<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03807921</url>
  </required_header>
  <id_info>
    <org_study_id>ANTIPRO</org_study_id>
    <nct_id>NCT03807921</nct_id>
  </id_info>
  <brief_title>Anticoagulation for Aortic Bioprosthesis (ANTIPRO)</brief_title>
  <official_title>Randomized Control Study of Anticoagulation With Warfarin Por Patients With Aortic Bioprosthesis vs Aspirin Only</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cirugia Cardiaca, Uruguay</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad de la Republica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Cirugia Cardiaca, Uruguay</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the clinical and hemodynamic outcome in patients after aortic valve
      replacement. Half of the patients will receive warfarin + aspirin and the other half will
      receive only aspirin. The investigators will focus mainly on early bioprosthesis
      degeneration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic bioprosthesis have the advantage that they do not require life-long anticoagulation.
      Current guidelines support the use of aspirin (AAS) 100 mg as a class I indication.

      Current evidence, mainly derived from transaortic valve implantation (TAVI) patients, have
      shown that aortic bioprosthesis suffer subclinical thrombosis which may explain the increase
      in gradient and bioprosthetic degeneration. Anticoagulation in this cases improve leaflet
      mobility and decrease in gradient. Evidence supporting early anticoagulation in patients with
      aortic bioprosthesis is not as strong as in the case of mitral bioprosthesis. Nonetheless,
      current American Heart Association/American College of Cardiology (AHA/ACC) guidelines
      recommend (IIa) the use of warfarin for at least 3 months after aortic valve replacement.

      The aim is to conduct a single blinded (echocardiographist) randomized control study in
      patients who receive an aortic bioprosthesis. Comparison will be performed between the use of
      warfarin + aspirin vs aspirin alone. Duration of anticoagulation will be for 3 months and
      patients follow-up for 1 year. Clinical and echocardiographic evaluation will be performed in
      every patients. Some patients will undergo Positron Emission Tomography (PET-Scan).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transprosthetic aortic gradient</measure>
    <time_frame>3 months and 1 year</time_frame>
    <description>Change in Transprosthetic maximum gradient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in New York Heart Association (NYHA) class</measure>
    <time_frame>1 year</time_frame>
    <description>NYHA class</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>3 months and 1 year</time_frame>
    <description>number of patients admitted due to Genitourinary (GU) or Gastrointestinal (GI) bleeding, pericardial tamponade, pleural effusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embolic events</measure>
    <time_frame>3 months and 1 year</time_frame>
    <description>Number of patients with cerebral and peripheral ischemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prosthetic leak</measure>
    <time_frame>3 months and 1 year</time_frame>
    <description>Change in severity of prosthetic and paraprosthetic leakage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Disease</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <condition>Aortic Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Warfarin will be started 48-72h after aortic valve replacement. Dose will be 5 mg daily in order to obtain an Internation normal ratio (INR) of 2-3. Warfarin treatment will continue for 3 months.
Aspirin will be administered 100 mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin will be started 48-72h after aortic valve replacement. Dose will be 100 mg daily. Patients who undergo coronary artery revascularization will receive 325 mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Oral anticoagulation</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Choice</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Antiplatelet treatment</description>
    <arm_group_label>Aspirin only</arm_group_label>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>AAS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with indication of aortic valve replacement with bioprosthesis

        Exclusion Criteria:

          -  Concomitant mitral valve replacement

          -  Previous atrial fibrillation

          -  Previous use oral anticoagulation

          -  Contraindication for the use of oral anticoagulation (high risk of bleeding,
             intolerance, allergy)

          -  Jehovah witness

          -  Platelet count below 90,000.

          -  Liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Dayan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cirugia Cardiaca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diego Freire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Cardiovascular Universitario</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victor Dayan, MD, PhD</last_name>
    <phone>59899647288</phone>
    <email>victor_dayan@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Cardiovascular Universitario</name>
      <address>
        <city>Montevideo</city>
        <country>Uruguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Dayan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cirugia Cardiaca</name>
      <address>
        <city>Montevideo</city>
        <country>Uruguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Dayan, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Uruguay</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2019</study_first_posted>
  <last_update_submitted>January 22, 2019</last_update_submitted>
  <last_update_submitted_qc>January 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cirugia Cardiaca, Uruguay</investigator_affiliation>
    <investigator_full_name>Victor Dayan</investigator_full_name>
    <investigator_title>Cardiac Surgeon</investigator_title>
  </responsible_party>
  <keyword>aortic valve replacement</keyword>
  <keyword>bioprosthesis</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>From January 2019</ipd_time_frame>
    <ipd_access_criteria>Protocol will be shared by email. Investigators interested should send email to the PI who will evaluate the solicitude.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

